Objective—To determine the effect of maternally
derived antibodies on induction of protective immune
responses against bovine viral diarrhea virus (BVDV)
type II in young calves vaccinated with a modified-live
bovine viral diarrhea virus (BVDV) type I vaccine.
Design—Blinded controlled challenge study.
Animals—24 neonatal Holstein and Holstein-cross
calves that were deprived of maternal colostrum and
fed pooled colostrum that contained a high concentration
of (n = 6) or no (18) antibodies to BVDV.
Procedure—At 10 to 14 days of age, 6 seropositive
and 6 seronegative calves were given a combination
vaccine containing modified-live BVDV type I. All
calves were kept in isolation for 4.5 months. Six
calves of the remaining 12 untreated calves were vaccinated
with the same combination vaccine at approximately
4 months of age. Three weeks later, all calves
were challenged intranasally with a virulent BVDV
Results—Seronegative unvaccinated calves and
seropositive calves that were vaccinated at 2 weeks
of age developed severe disease, and 4 calves in each
of these groups required euthanasia. Seronegative
calves that were vaccinated at 2 weeks or 4 months
of age developed only mild or no clinical signs of disease.
Conclusions and Clinical Relevance—Results indicate
that a single dose of a modified-live BVDV type-I
vaccine given at 10 to 14 days of age can protect susceptible
young calves from virulent BVDV type II infection
for at least 4 months, but high concentrations of
BVDV-specific maternally derived antibodies can block
the induction of the response. (J Am Vet Med Assoc
Animals—Client-owned cats of any breed with naturally occurring skin infections with associated clinical signs and confirmatory bacteriologic culture results.
Procedures—Cats with clinical signs of skin and soft tissue infection were randomly allocated to receive a single dose of cefovecin (8 mg/kg [3.6 mg/lb], SC) followed by placebo drops administered orally once daily for 14 days or 1 SC placebo injection followed by cefadroxil (22 mg/kg [10 mg/lb], PO, once daily for 14 days). Only one 14-day treatment course was permitted.
Results—Effectiveness of cefovecin in the treatment of cats with abscesses and infected wounds was similar to that of cefadroxil. At the final assessment on day 28, 97% (86/89) of cefovecin-treated cats and 91% (80/88) of cefadroxil-treated cats were considered treatment successes. There were no serious adverse events or deaths related to treatment.
Conclusions and Clinical Relevance—1 SC injection of 8 mg of cefovecin/kg for the treatment of cats with naturally occurring skin infections (wounds and abscesses) was safe and as effective as cefadroxil administered orally at 22 mg/kg, once daily for 14 days.